259 related articles for article (PubMed ID: 35870472)
41. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
42. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
43. Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
Ghorashian S; Jacoby E; De Moerloose B; Rives S; Bonney D; Shenton G; Bader P; Bodmer N; Quintana AM; Herrero B; Algeri M; Locatelli F; Vettenranta K; Gonzalez B; Attarbaschi A; Harris S; Bourquin JP; Baruchel A
Lancet Haematol; 2022 Oct; 9(10):e766-e775. PubMed ID: 36084658
[TBL] [Abstract][Full Text] [Related]
44. Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
Withycombe JS; Post-White JE; Meza JL; Hawks RG; Smith LM; Sacks N; Seibel NL
Pediatr Blood Cancer; 2009 Dec; 53(7):1249-54. PubMed ID: 19688832
[TBL] [Abstract][Full Text] [Related]
45. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
46. Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study.
Frey N; Jang JH; Szer J; Illés Á; Kim HJ; Ram R; Chong BH; Rowe JM; Borisenkova E; Liesveld J; Winer ES; Cherfi A; Aslanis V; Ghaznawi F; Strickland S
Lancet Haematol; 2019 Mar; 6(3):e122-e131. PubMed ID: 30704923
[TBL] [Abstract][Full Text] [Related]
47. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
48. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group.
Abromowitch M; Sposto R; Perkins S; Zwick D; Siegel S; Finlay J; Cairo MS;
Br J Haematol; 2008 Oct; 143(2):261-7. PubMed ID: 18759768
[TBL] [Abstract][Full Text] [Related]
49. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
50. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
Ravandi F; Assi R; Daver N; Benton CB; Kadia T; Thompson PA; Borthakur G; Alvarado Y; Jabbour EJ; Konopleva M; Takahashi K; Kornblau S; DiNardo CD; Estrov Z; Flores W; Basu S; Allison J; Sharma P; Pierce S; Pike A; Cortes JE; Garcia-Manero G; Kantarjian HM
Lancet Haematol; 2019 Sep; 6(9):e480-e488. PubMed ID: 31400961
[TBL] [Abstract][Full Text] [Related]
51. Treatment abandonment in childhood acute lymphoblastic leukaemia in China: a retrospective cohort study of the Chinese Children's Cancer Group.
Cai J; Yu J; Zhu X; Hu S; Zhu Y; Jiang H; Li C; Fang Y; Liang C; Ju X; Tian X; Zhai X; Hao J; Hu Q; Wang N; Jiang H; Sun L; Li CK; Pan K; Yang M; Shen S; Cheng C; Ribeiro RC; Pui CH; Tang J;
Arch Dis Child; 2019 Jun; 104(6):522-529. PubMed ID: 30705079
[TBL] [Abstract][Full Text] [Related]
52. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group.
Termuhlen AM; Smith LM; Perkins SL; Lones M; Finlay JL; Weinstein H; Gross TG; Abromowitch M
Br J Haematol; 2013 Sep; 162(6):792-801. PubMed ID: 23889312
[TBL] [Abstract][Full Text] [Related]
53. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
[TBL] [Abstract][Full Text] [Related]
54. No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.
Kato M; Koh K; Manabe A; Saito T; Hasegawa D; Isoyama K; Kinoshita A; Maeda M; Okimoto Y; Kajiwara M; Kaneko T; Sugita K; Kikuchi A; Tsuchida M; Ohara A
Br J Haematol; 2014 Feb; 164(3):376-83. PubMed ID: 24164537
[TBL] [Abstract][Full Text] [Related]
55. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
[TBL] [Abstract][Full Text] [Related]
56. Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.
Maloney KW; Devidas M; Wang C; Mattano LA; Friedmann AM; Buckley P; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Kadan-Lottick N; Loh ML; Matloub YH; Marshall DT; Stork LC; Raetz EA; Wood B; Hunger SP; Carroll WL; Winick NJ
J Clin Oncol; 2020 Feb; 38(6):602-612. PubMed ID: 31825704
[TBL] [Abstract][Full Text] [Related]
57. Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis.
Margolis EB; Hakim H; Dallas RH; Allison KJ; Ferrolino J; Sun Y; Pui CH; Yao J; Chang TC; Hayden RT; Jeha S; Tuomanen EI; Tang L; Rosch JW; Wolf J
Lancet Microbe; 2021 Apr; 2(4):e159-e167. PubMed ID: 34355208
[TBL] [Abstract][Full Text] [Related]
58. Clinico-Haematologic Parameters And Assessment Of Post-Induction Status In Acute Lymphoblastic Leukaemia.
Niaz H; Malik HS; Mahmood R; Mehmood A; Zaidi SA; Nisar U
J Ayub Med Coll Abbottabad; 2022; 34(3):458-462. PubMed ID: 36377156
[TBL] [Abstract][Full Text] [Related]
59. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
Miller TP; Li Y; Kavcic M; Troxel AB; Huang YS; Sung L; Alonzo TA; Gerbing R; Hall M; Daves MH; Horton TM; Pulsipher MA; Pollard JA; Bagatell R; Seif AE; Fisher BT; Luger S; Gamis AS; Adamson PC; Aplenc R
J Clin Oncol; 2016 May; 34(13):1537-43. PubMed ID: 26884558
[TBL] [Abstract][Full Text] [Related]
60. Induction-remission response in peadiatric acute lymphoblastic leukaemia, Lahore protocol versus UKALL 2011 interim guidelines.
Khan S; Anwar S; Latif MF; Farooq A; Faizan M
J Pak Med Assoc; 2020 Apr; 70(4):591-596. PubMed ID: 32296200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
